TW201245224A - Cytotoxic t cell inducing composition - Google Patents

Cytotoxic t cell inducing composition Download PDF

Info

Publication number: TW201245224A
Authority: TW; Taiwan
Prior art keywords: cells; peptide; cytotoxic; cell; antibody
Prior art date: 2011-04-08

Application number

TW101105197A

Other languages

English (en)

Chinese (zh)

Inventor

Naohide Yamashita

Hitomi Nagayama

Shigeharu Fujita

Yukino Kimura

Original Assignee

Univ Tokyo

Tella Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-08

Filing date

2012-02-17

Publication date

2012-11-16

2012-02-17 Application filed by Univ Tokyo, Tella Inc filed Critical Univ Tokyo

2012-11-16 Publication of TW201245224A publication Critical patent/TW201245224A/zh

Links

239000000203 mixture Substances 0.000 title claims abstract description 31
210000001151 cytotoxic T lymphocyte Anatomy 0.000 title claims abstract description 29
230000001939 inductive effect Effects 0.000 title claims abstract description 26
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 193
108091007433 antigens Proteins 0.000 claims abstract description 66
102000036639 antigens Human genes 0.000 claims abstract description 66
239000000427 antigen Substances 0.000 claims abstract description 64
206010028980 Neoplasm Diseases 0.000 claims abstract description 30
239000007787 solid Substances 0.000 claims abstract description 13
108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims abstract description 11
238000011282 treatment Methods 0.000 claims abstract description 10
210000004881 tumor cell Anatomy 0.000 claims abstract description 9
102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims abstract 7
125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
210000004027 cell Anatomy 0.000 claims description 334
210000004700 fetal blood Anatomy 0.000 claims description 70
241000282414 Homo sapiens Species 0.000 claims description 45
210000004369 blood Anatomy 0.000 claims description 43
239000008280 blood Substances 0.000 claims description 43
231100000433 cytotoxic Toxicity 0.000 claims description 36
230000001472 cytotoxic effect Effects 0.000 claims description 36
238000000034 method Methods 0.000 claims description 33
210000003958 hematopoietic stem cell Anatomy 0.000 claims description 28
108090000623 proteins and genes Proteins 0.000 claims description 26
239000008194 pharmaceutical composition Substances 0.000 claims description 21
150000001413 amino acids Chemical class 0.000 claims description 20
102000004169 proteins and genes Human genes 0.000 claims description 19
206010036790 Productive cough Diseases 0.000 claims description 12
230000000890 antigenic effect Effects 0.000 claims description 12
210000003802 sputum Anatomy 0.000 claims description 12
208000024794 sputum Diseases 0.000 claims description 12
241000700605 Viruses Species 0.000 claims description 11
210000001185 bone marrow Anatomy 0.000 claims description 10
210000004504 adult stem cell Anatomy 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
210000000130 stem cell Anatomy 0.000 claims description 7
241000701022 Cytomegalovirus Species 0.000 claims description 6
210000001671 embryonic stem cell Anatomy 0.000 claims description 6
230000003612 virological effect Effects 0.000 claims description 6
210000001744 T-lymphocyte Anatomy 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
230000003013 cytotoxicity Effects 0.000 claims description 2
231100000135 cytotoxicity Toxicity 0.000 claims description 2
150000003431 steroids Chemical class 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
238000004113 cell culture Methods 0.000 claims 1
230000003394 haemopoietic effect Effects 0.000 claims 1
230000001988 toxicity Effects 0.000 claims 1
231100000419 toxicity Toxicity 0.000 claims 1
230000006698 induction Effects 0.000 abstract description 31
239000003814 drug Substances 0.000 abstract description 4
229940079593 drug Drugs 0.000 abstract description 3
238000005516 engineering process Methods 0.000 abstract description 3
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 82
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 81
230000000638 stimulation Effects 0.000 description 79
101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 63
102100022748 Wilms tumor protein Human genes 0.000 description 61
102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 48
108010075704 HLA-A Antigens Proteins 0.000 description 48
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 46
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 46
210000004443 dendritic cell Anatomy 0.000 description 32
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 32
239000002609 medium Substances 0.000 description 32
239000011324 bead Substances 0.000 description 30
238000000684 flow cytometry Methods 0.000 description 28
108010021994 cytomegalovirus matrix protein 65kDa Proteins 0.000 description 20
210000002966 serum Anatomy 0.000 description 18
201000011510 cancer Diseases 0.000 description 17
238000002474 experimental method Methods 0.000 description 17
108010021727 HLA-A*24:02 antigen Proteins 0.000 description 16
238000011419 induction treatment Methods 0.000 description 15
102000004196 processed proteins & peptides Human genes 0.000 description 13
238000010186 staining Methods 0.000 description 11
230000005291 magnetic effect Effects 0.000 description 10
102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
230000003993 interaction Effects 0.000 description 9
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
102000003812 Interleukin-15 Human genes 0.000 description 7
108090000172 Interleukin-15 Proteins 0.000 description 7
239000000463 material Substances 0.000 description 7
239000007790 solid phase Substances 0.000 description 7
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 6
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 6
238000002156 mixing Methods 0.000 description 6
210000005259 peripheral blood Anatomy 0.000 description 6
239000011886 peripheral blood Substances 0.000 description 6
230000035755 proliferation Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
108090001008 Avidin Proteins 0.000 description 5
108010058607 HLA-B Antigens Proteins 0.000 description 5
102000043129 MHC class I family Human genes 0.000 description 5
108091054437 MHC class I family Proteins 0.000 description 5
230000002776 aggregation Effects 0.000 description 5
238000004220 aggregation Methods 0.000 description 5
230000009977 dual effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000003756 stirring Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
239000012634 fragment Substances 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
238000002372 labelling Methods 0.000 description 4
239000006249 magnetic particle Substances 0.000 description 4
239000011325 microbead Substances 0.000 description 4
101100326920 Caenorhabditis elegans ctl-1 gene Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
-1 HLA diterpenoid Chemical class 0.000 description 3
241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
108010002586 Interleukin-7 Proteins 0.000 description 3
102000000704 Interleukin-7 Human genes 0.000 description 3
101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 3
108010081208 RMFPNAPYL Proteins 0.000 description 3
108010090804 Streptavidin Proteins 0.000 description 3
108700020467 WT1 Proteins 0.000 description 3
102000040856 WT1 Human genes 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000556 agonist Substances 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
239000011616 biotin Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000012258 culturing Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
210000005087 mononuclear cell Anatomy 0.000 description 3
229940126619 mouse monoclonal antibody Drugs 0.000 description 3
230000035772 mutation Effects 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
241000701024 Human betaherpesvirus 5 Species 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
108010002687 Survivin Proteins 0.000 description 2
108091008874 T cell receptors Proteins 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
102000003425 Tyrosinase Human genes 0.000 description 2
108060008724 Tyrosinase Proteins 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000007012 clinical effect Effects 0.000 description 2
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
229960002986 dinoprostone Drugs 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
102000046004 human WT1 Human genes 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000008188 pellet Substances 0.000 description 2
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
CXZFXHGJJPVUJE-CIUDSAMLSA-N Ala-Cys-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O)N CXZFXHGJJPVUJE-CIUDSAMLSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
101150009389 BZLF1 gene Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
AGNIXLPCPQAPSB-SXHLWKDOSA-N CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=C(O)C=C1 Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=C(O)C=C1 AGNIXLPCPQAPSB-SXHLWKDOSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
VXDXZGYXHIADHF-YJRXYDGGSA-N Cys-Tyr-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VXDXZGYXHIADHF-YJRXYDGGSA-N 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
101150059079 EBNA1 gene Proteins 0.000 description 1
101150034762 EBNA3 gene Proteins 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
108091034120 Epstein–Barr virus-encoded small RNA Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
108010088729 HLA-A*02:01 antigen Proteins 0.000 description 1
108010052199 HLA-C Antigens Proteins 0.000 description 1
235000005206 Hibiscus Nutrition 0.000 description 1
235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
241001075721 Hibiscus trionum Species 0.000 description 1
101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 1
101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 1
101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
101710192602 Latent membrane protein 1 Proteins 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
YNOVBMBQSQTLFM-DCAQKATOSA-N Met-Asn-Leu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O YNOVBMBQSQTLFM-DCAQKATOSA-N 0.000 description 1
208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
GLUYKHMBGKQBHE-JYJNAYRXSA-N Phe-Val-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 GLUYKHMBGKQBHE-JYJNAYRXSA-N 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
101150055297 SET1 gene Proteins 0.000 description 1
241000239226 Scorpiones Species 0.000 description 1
108010017842 Telomerase Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
GUIYPEKUEMQBIK-JSGCOSHPSA-N Val-Tyr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(O)=O GUIYPEKUEMQBIK-JSGCOSHPSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000003915 cell function Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000005206 flow analysis Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
108010081551 glycylphenylalanine Proteins 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000005484 gravity Effects 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
102000056003 human IL15 Human genes 0.000 description 1
102000055229 human IL4 Human genes 0.000 description 1
102000052622 human IL7 Human genes 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
239000009004 jinqing Substances 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000007885 magnetic separation Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
201000011216 nasopharynx carcinoma Diseases 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035807 sensation Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
238000012549 training Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000012795 verification Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000001018 virulence Effects 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1
239000012463 white pigment Substances 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

TW101105197A 2011-04-08 2012-02-17 Cytotoxic t cell inducing composition TW201245224A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2011086625A JP5840857B2 (ja)	2011-04-08	2011-04-08	細胞傷害性ｔ細胞誘導用組成物
PCT/JP2012/053396 WO2012137538A1 (ja)	2011-04-08	2012-02-14	細胞傷害性ｔ細胞誘導用組成物

Publications (1)

Publication Number	Publication Date
TW201245224A true TW201245224A (en)	2012-11-16

Family

ID=46968942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW101105197A TW201245224A (en)	2011-04-08	2012-02-17	Cytotoxic t cell inducing composition

Country Status (3)

Country	Link
JP (1)	JP5840857B2 (ja)
TW (1)	TW201245224A (ja)
WO (1)	WO2012137538A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106170297A (zh) *	2013-09-20	2016-11-30	纪念斯隆-凯特琳癌症中心	用于wt‑1‑阳性疾病的组合/辅助疗法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA45489A (fr)	2015-10-22	2018-08-29	Juno Therapeutics Gmbh	Procédés de culture de cellules, kits et appareil associés
MA43590A (fr) *	2016-01-08	2018-11-14	Taiho Pharmaceutical Co Ltd	Agent antitumoral contenant un immunomodulateur et un amplificateur d'effet antitumoral
JP2018007599A (ja) *	2016-07-12	2018-01-18	株式会社ガイアバイオメディシン	樹状細胞集団の調製方法
CN111032850A (zh)	2017-04-27	2020-04-17	朱诺治疗学有限公司	寡聚粒子试剂及其使用方法
JP2023078487A (ja) *	2020-04-08	2023-06-07	アステラス製薬株式会社	がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1623017T3 (da) *	2003-05-08	2011-01-10	Life Technologies Corp	Frembringelse og isolering af antigenspecifikke T-celler
JP5070045B2 (ja) *	2004-05-27	2012-11-07	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	新規人工抗原提示細胞およびそれらの用途

2011
- 2011-04-08 JP JP2011086625A patent/JP5840857B2/ja not_active Expired - Fee Related
2012
- 2012-02-14 WO PCT/JP2012/053396 patent/WO2012137538A1/ja active Application Filing
- 2012-02-17 TW TW101105197A patent/TW201245224A/zh unknown

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106170297A (zh) *	2013-09-20	2016-11-30	纪念斯隆-凯特琳癌症中心	用于wt‑1‑阳性疾病的组合/辅助疗法

Also Published As

Publication number	Publication date
WO2012137538A1 (ja)	2012-10-11
JP5840857B2 (ja)	2016-01-06
JP2012219062A (ja)	2012-11-12

Publication	Publication Date	Title
US20230145991A1 (en)	2023-05-11	T cell compositions for immunotherapy
JP6522671B2 (ja)	2019-05-29	自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法
KR102048228B1 (ko)	2019-11-25	Ｔ 세포 자극용 엑소좀 및 이의 약제학적 용도
JP6126804B2 (ja)	2017-05-10	Ｔ細胞受容体のクローニング方法
JP2021164461A (ja)	2021-10-14	キメラ抗原受容体及び他の受容体の発現に対するｔ細胞
JP2017536843A (ja)	2017-12-14	養子細胞療法のためのｔ細胞株及びそのドナーの選択方法
TWI334442B (en)	2010-12-11	Process for producing cytotoxic lymphocyte
JP5729887B2 (ja)	2015-06-03	Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
TW201245224A (en)	2012-11-16	Cytotoxic t cell inducing composition
CN110713977B (zh)	2022-05-27	一种cd8 t细胞的培养扩增方法
WO2019205783A1 (zh)	2019-10-31	人类dc细胞扩增方法和人类dc细胞资源库
CN114230658A (zh)	2022-03-25	新型冠状病毒特异性t细胞受体和其用途
JP2023166443A (ja)	2023-11-21	樹状細胞治療のための方法および使用
JP6903866B2 (ja)	2021-07-14	血液由来単球の増殖誘導方法
JP2017169566A (ja)	2017-09-28	Ｔ細胞レセプターとその利用
JP2007521803A (ja)	2007-08-09	レギュレーター／サプレッサーｔリンパ球の同定および調製のための方法、その組成物、並びにその使用
KR20200097253A (ko)	2020-08-18	T 세포 조성물의 생산방법
Haveman et al.	2013	Selection of perforin expressing CD4+ adenovirus-specific T-cells with artificial antigen presenting cells
US20240252644A1 (en)	2024-08-01	Person-tailored t cell composition targeting merkel cell carcinoma
KR20120054018A (ko)	2012-05-29	일과성 생착 ｃｔｌ을 포함하는 의약품 조성물
EP4347794A1 (en)	2024-04-10	Person-tailored t cell composition targeting merkel cell carcinoma
JP2024103547A (ja)	2024-08-01	免疫療法向けのｔ細胞組成物
JP2023019830A (ja)	2023-02-09	ｉＰＳ細胞に対する免疫反応を評価する方法
Meckiff	2021	Evolution of the human CD4+ T cell response to Epstein-Barr virus infection-analysis of systemic and local immune responses
JP6508873B2 (ja)	2019-05-08	抗原特異的ｔ細胞受容体の取得方法

TW201245224A - Cytotoxic t cell inducing composition - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=46968942

Family Applications (1)

Country Status (3)

Cited By (1)

Families Citing this family (5)

Family Cites Families (2)

Cited By (1)

Also Published As

Similar Documents